More stories

  • in

    The 2022 CNBC Disruptor 50 list: Meet the next generation of Silicon Valley

    The 2022 CNBC Disruptors are 50 private companies growing and innovating through a challenging market and changed world, while inspiring change in their larger, incumbent competitors.

    In the tenth annual Disruptor 50 list, CNBC highlights private companies that grew through the ups and downs of the pandemic and are poised to meet increasing economic and consumer challenges.
    All told, these firms have raised a half-trillion dollars in venture capital. At least 41 are unicorns, with valuations of $1 billion or more – 14 are valued at over $10 billion. But becoming a unicorn has become all too common, and as market volatility pressures valuations in both public and private markets, other stats stand out: 

    Forty of the companies have a social or environmental purpose that is core to their business model. Ten of this year’s Disruptors are from the logistics sector, tackling the broken global supply chain that has fueled four-decade high inflation. Eight are reducing costs in a bloated health-care system and reaching underserved populations. Several more are dedicated to the climate crisis. Nine of this year’s Disruptors have a female founder. Sixteen feature CEOs from racial and ethnic minorities.  
    The 50 companies selected using the proprietary Disruptor 50 methodology have raised over $56 billion in venture capital, according to PitchBook, at an implied Disruptor 50 valuation of more than $552 billion.

    1
    Flexport
    Overwhelming the supply chain bottleneck

    2
    Brex
    The start-up world’s finance department

    3
    Lineage Logistics
    On top of the global food supply’s temperature

    4
    Canva
    The feature presentation

    5
    Guild Education
    Work. Study.

    6
    Convoy
    Trucking as we’ve known it stops here

    7
    Blockchain.com
    Web3’s dot com

    8
    Stripe
    Making the internet pay

    9
    Dapper Labs
    The shot Michael Jordan and Kevin Durant are taking on decentralization

    10
    Pony.ai
    Hand over the reins.

    11
    Checkout.com
    A rival to the Stripe swipe

    12
    Chime
    A challenger bank in a challenging fintech market

    13
    Discord
    How digital natives converse

    14
    Flock Freight
    Fully loaded

    15
    Medable
    The virtual clinical trial

    16
    Truepill
    The infrastructure for online pharmacy

    17
    Arctic Wolf
    A cyber defender from up north

    18
    CloudTrucks
    Big ideas for the Big Road

    19
    Maven Clinic
    Putting women first in health

    20
    Monarch Tractor
    1 driver. 8 tractors. All electric.

    21
    Fanatics
    Taking sports merch into the metaverse

    22
    Tala
    The world’s local lender

    23
    Anduril Industries
    Engineering an autonomous military arsenal

    24
    Workato
    Office work automated

    25
    Lacework
    Cybercrime’s lie detector

    26
    Somatus
    Kidney care without the dialysis centers

    27
    Gopuff
    All your instant needs fulfilled

    28
    Virta Health
    Don’t treat diabetes; reverse it.

    29
    Zipline
    A life-saving drone, with a Walmart side hustle

    30
    CarbonCure
    Carbon to concrete

    31
    Jüsto
    Mexico’s answer to Walmart, and FreshDirect, and Gopuff

    32
    Biobot Analytics
    A wastewater virus hunter

    33
    Airtable
    The code for every knowledge worker

    34
    Databricks
    The start-up world’s biggest data bet

    35
    DataRobot
    A one-trillion predictions market maker

    36
    Relativity Space
    An Elon Musk reusable rocket competitor

    37
    NEXT Insurance
    Digital small business insurance

    38
    Ro
    Planning to be a digital health survivor

    39
    Airspace
    Critical on-demand delivery for the pandemic era

    40
    Thrasio
    A consumer products giant for the digital age.

    41
    Cybereason
    A bird’s eye view

    42
    BlocPower
    Building net-zero cities

    43
    ŌURA
    The one ring to rule wearables

    44
    MoonPay
    The biggest celebrity bet on crypto

    45
    Zum
    School bus magic

    46
    Exotec
    France’s warehouse robot unicorn

    47
    Plaid
    A bridge from fintech to bank

    48
    Cityblock Health
    Healthtech for low-income America

    49
    Impossible Foods
    From plant-based fad to fixture

    50
    Envoy
    Back to the office of the future More

  • in

    26. Somatus

    The 2022 CNBC Disruptors are 50 private companies growing and innovating through a challenging market and changed world, while inspiring change in their larger, incumbent competitors.

    Founders: Ikenna Okezie (CEO), Tony WeltersLaunched: 2017Headquarters: McLean, VirginiaFunding: $490.1 million (PitchBook)Valuation: $2.5 billion (PitchBook)Key technologies: Artificial intelligence, machine learningIndustry: Health carePrevious appearances on Disruptor 50 List: 0

    Persephone Kavallines

    When Warren Buffett buys big into a stock, and keeps buying, it’s typically a sign that the billionaire investor thinks a company has close to monopoly-like power over some market. That’s the case with kidney care company DaVita, which Buffett’s Berkshire Hathaway started buying several years ago and in which it now holds a stake worth well north of 30%. DaVita is among a handful of companies that dominate the market for kidney care and dialysis. But big incumbents will also attract the attention of disruptive start-ups, sometimes starting out from with their own ranks.

    Somatus, a kidney care provider, was co-founded by former DaVita executive and doctor Ikenna Okezia, who is its CEO. Since 2016, Somatus has been building a network that works with health plans and provider groups to lower the cost of kidney care, using locally-based providers and in-home care for patients.
    The existing approach built by companies including DaVita relies on the physical infrastructure of bricks-and-mortar dialysis centers. With the heavy investment that went into building this system, start-ups see an opportunity in new, less real-estate intensive models.

    More coverage of the 2022 CNBC Disruptor 50

    Globally, there as many as two million people suffering from kidney failure, and the disease is increasing by 5% to 7% a year.
    In the U.S., specifically, kidney disease affects 15% of the U.S. adult population, over 37 million people, and disproportionately is suffered by the Black population and low-income Americans. This has led to criticism that the system has been allowed to remain as it is, in part due to the nature of the patient population. It’s a claim made by Andy Slavitt, former managing director of The Centers for Medicare & Medicaid Services under President Barack Obama, who has invested in several companies in the kidney care disruptor space through his VC firm Town Hall Ventures, including Somatus. He was previously on the Somatus board.
    According to critics, kidney care falls into the frustrating health care category of high costs and questionable outcomes. For severe cases, the price tag for dialysis is steep, with end-stage kidney disease patients paying as much as $15,000 per month, according to a recent study. The 750,000 Americans who live with kidney failure represent 7% of Medicare’s budget, with dialysis costing Medicare $90,000 per patient annually, a total running into the tens of billions of dollars. 

    As the status quo, high-cost incumbents are targeted, Somatus is in an increasingly crowded field of new companies in the kidney care space, which includes Strive Health, Cricket Health and Monogram Health. And the Somatus founder isn’t the only member of the “DaVita mafia” coming for their former employer.  Strive Health was founded by two former DaVita executives. DaVita and its peers including Fresenius are aware of the changes taking place in the market and are making their own investments in new approaches.
    Somatus continues to secure new capital from investors and notable health-care market deals. In February, it raised over $325 million in a Series E funding round at a valuation of over $2.5 billion, with investors including Wellington Management and Fidelity. In November of last year, Anthem made a strategic investment in Somatus, and announced a long-term, multi-year partnership to expand the company’s geographic footprint, which is expected to reach 35 states and 150,000 patients this year across Medicare, Medicare Advantage, Medicaid, and commercial plans.

    Sign up for our weekly, original newsletter that goes beyond the annual Disruptor 50 list, offering a closer look at list-making companies and their innovative founders. More

  • in

    28. Virta Health

    The 2022 CNBC Disruptors are 50 private companies growing and innovating through a challenging market and changed world, while inspiring change in their larger, incumbent competitors.

    Founders: Sami Inkinen (CEO), Stephen Phinney, Jeff VolekLaunched: 2015Headquarters: San FranciscoFunding: $366 millionValuation: $2 billionKey technologies: Artificial intelligence, machine learningIndustry: Health carePrevious appearances on Disruptor 50 List: 1 (No. 29 in 2019)

    Persephone Kavallines

    Virta Health’s origin story is well-known: Sami Inkinen, founder of real estate start-up Trulia, a fitness enthusiast and Ironman competitor, discovered to his surprise he was pre-diabetic and decided in 2014 to do something about it. As a start-up entrepreneur, he co-founded Virta Health with the mission of reversing type 2 diabetes in 100 million people by 2025.

    There are 34 million Americans living with diabetes and 88 million who are pre-diabetic at an annual cost of well over $300 billion to the U.S. economy, and that cost has been increasing fast in recent years, according to the American Diabetes Association.
    Drugs treating diabetes by keeping blood sugar levels under control have been the health-care norm and major drug companies have made a fortune, with U.S. sales reaching $74 billion in 2020, up from just $7 billion two decades ago, according to IQVIA data cited by Reuters. Type 2 diabetes is also linked closely to additional business models in the obesity market, from weight loss companies and apps to bariatric surgery. 

    More coverage of the 2022 CNBC Disruptor 50

    Many patients are told to eat less and exercise more, but Virta Health aims to upend the status quo in general wellness advice, combined with drug reliance. Using technology to connect patients with coaching and remote care, as well as nutritional science, it wants to change the way the medical community thinks about diabetes as a chronic condition — reversing the disease rather than poorly managing it and exposing patients to the additional risks that go along with medication. 
    The company raised another $133 million last April, nearly doubling its valuation to $2 billion. But it isn’t alone in promoting a new technology-led model for chronic health conditions, with Teladoc (it acquired chronic care company Livongo), Omada Health, and Onduo among rivals that have seen increased funding and partnerships. 
    What sets Virta apart from its competitors is going beyond managing the disease through technology, to seeking actual reversal of it. Each patient has a remote care team — a health coach and a medical provider, and receives behavioral support and encouragement from their coaches and an online community of their peers. Early-adopters have been vocal advocates for its approach: one profiled by CNBC in 2020 tattooed the company’s logo on her arm. But the science remains young and the research limited.

    Part of its approach requires a drastic reduction in carbohydrate calories (the science of nutritional ketonosis), and it has yet to be proven that this is a sustainable approach for long-term diabetes management. Virta clinical trial results from 2019, while showing both reversal and in other cases remission of diabetes, only cover a few years of treatment. In 2021, it published peer-reviewed research on Virta’s treatment of prediabetes, showing that only 3% of trial participants progress to type 2 diabetes during the first two years. Additional research has shown that its approach can reduce another byproduct of diabetes: depression in patients on conventional treatment.
    The Virta Health model is being embraced by more corporate health care plans, health systems and insurers. Virta has expanded to over 200 customers as of late last year, including major insurers Providence Health Plan and Humana, which signed a deal last year to offer Virta’s diabetes reversal treatment to employer groups. It now works with more than 20 national and regional health plans, marking 133% year-over-year growth with large insurer customers, nearly half of which now offer Virta’s diabetes reversal treatment to their employer groups. That represents thousands of companies and over five million individuals. The company is growing its staff to keep up with the deals, doubling headcount to 400-plus employees in 2021. 
    The approach is gaining more acceptance from the academic community, if not by specific name in the case of Virta, at least in terms of the concept of reversing the disease as medical aim. In August of last year, the American Diabetes Association, the Endocrine Society, the European Association for the Study of Diabetes, and Diabetes UK released a consensus report that defined diabetes reversal for the first time.

    Sign up for our weekly, original newsletter that goes beyond the annual Disruptor 50 list, offering a closer look at list-making companies and their innovative founders. More

  • in

    A huge tidal power testing facility is looking to simulate decades of harsh sea conditions

    Sustainable Energy

    Sustainable Energy
    TV Shows

    A £4.6 million ($5.64 million) facility that can test tidal turbine blades under strenuous conditions has been officially opened.
    The University of Edinburgh says the site is the “world’s first rapid testing facility for tidal turbine blades.”
    While there is excitement about the potential of marine energy, the footprint of tidal stream and wave projects remains very small compared to other renewables.

    An image of the £4.6 million FastBlade facility. Scotland has a long association with North Sea oil and gas production, but in recent years it’s also become a hub for companies and projects focused on tidal power and marine energy in general.
    Jeff J Mitchell | Getty Images News | Getty Images

    A £4.6 million ($5.64 million) facility that can test tidal turbine blades under strenuous conditions has been officially opened, with those behind it hoping it will accelerate the development of marine energy technology and lower costs.
    In a statement at the end of last week, the University of Edinburgh said the site was the “world’s first rapid testing facility for tidal turbine blades.”

    It added that the FastBlade facility would use a 75 metric ton reaction frame that was able to apply “powerful forces on turbine blades more than 50 feet long.”
    FastBlade is a partnership between aerospace firm Babcock International and the university that’s backed by a grant of £1.8 million from the U.K. government. The testing center is located in the town of Rosyth.
    Tests on blades, the university said, would be undertaken “using a system of powerful hydraulic cylinders, which, in less than three months, can simulate the stresses placed on the structures during two decades at sea.”
    Conchúr Ó Brádaigh, who is head of the university’s school of engineering, said FastBlade would be “the world’s first dedicated fatigue test facility for tidal turbine blades.”
    He went on to state it would also “help maintain the globally leading position of Scottish tidal turbine developers in the race to find sources of clean and secure power.”

    The University of Edinburgh said the FastBlade technology could also be harnessed to test wing components for aircraft and lightweight bridge sections.

    Read more about energy from CNBC Pro

    Scotland has a long association with North Sea oil and gas production, but in recent years it’s also become a hub for companies and projects focused on tidal power and marine energy in general.
    These firms include tidal energy firm Nova Innovation and Orbital Marine Power, which is working on what it says is the “most powerful tidal turbine in the world.”
    In waters north of the Scottish mainland, the archipelago of Orkney is home to the European Marine Energy Centre, or EMEC, where wave and tidal energy developers can test and assess their tech in the open sea.
    European installations of tidal and wave energy capacity jumped in 2021, as the ocean energy sector saw deployments revert to pre-pandemic levels and a substantial increase in investment.
    In March, Ocean Energy Europe said 2.2 megawatts of tidal stream capacity was installed in Europe last year, compared to just 260 kilowatts in 2020. For wave energy, 681 kW was installed, which OEE said was a threefold increase.
    Globally, 1.38 MW of wave energy came online in 2021, while 3.12 MW of tidal stream capacity was installed. Capacity refers to the maximum amount of electricity installations can produce, not what they’re necessarily generating.While there is excitement about the potential of marine energy, the footprint of tidal stream and wave projects remains very small compared to other renewables.
    In 2021 alone, Europe installed 17.4 gigawatts of wind power capacity, according to figures from industry body WindEurope. More

  • in

    Abbott reaches agreement with FDA to reopen baby formula plant to ease nationwide shortage

    Under a consent decree, Abbott has agreed to address insanitary conditions that led to the contamination of its baby formula plant in Sturgis, Michigan.
    Abbott said it can restart the plant within two weeks.
    However, it would take six to eight weeks from the start of production for formula to arrive on store shelves, the company noted.

    A woman shops for baby formula at Target in Annapolis, Maryland, on May 16, 2022, as a nationwide shortage of baby formula continues due to supply chain crunches tied to the coronavirus pandemic that have already strained the countrys formula stock, an issue that was further exacerbated by a major product recall in February.
    Jim Watson | AFP | Getty Images

    Abbott reached an agreement with the Food and Drug Administration on Monday to reopen the company’s manufacturing plant in Michigan to help ease a nationwide shortage of baby formula, after the facility was closed due to bacterial contamination.
    FDA Commissioner Robert Califf said Abbott, under the conditions of the agreement, will correct insanitary conditions that led to the contamination and plant closure.

    “The public should rest assured that the agency will do everything possible to continue ensuring that infant and other specialty formulas produced by the company meet the FDA’s safety and quality standards,” Califf said in a statement.
    The agreement between Abbott and the FDA, called a consent decree, was approved by the U.S. District Court for the Western District of Michigan on Monday. Abbott can restart the Sturgis, Michigan, plant within two weeks, the company said. However, it said it would take six to eight weeks from the start of production for formula to arrive on store shelves.
    Mothers are struggling to find formula for their infants with shelves empty in many stores across the U.S. More than 40% of baby formula was out of stock nationwide during the week ended May 8, according to Datasembly, a retail data tracker. However, the FDA said Monday that nearly 80% of baby formula was in stock, citing data from Information Resources, another retail data company.
    The supply shortage was triggered in part by the closure of Abbott Nutrition’s manufacturing plant in Michigan after four infants who consumed formula from the facility fell ill from bacterial infections, two of whom subsequently died. Abbott is the largest infant formula manufacturer in the U.S.
    The Justice Department, in a complaint on behalf of the FDA, alleged that products manufactured at Abbott’s Sturgis facility were adulterated because they were made under insanitary conditions. 

    Inspections by the FDA found the presence of Cronobacter sakazakii, a bacteria that can cause blood infection, at the factory. Abbott internal records also showed that the company destroyed some of its product due to the presence of the bacteria at the plant, according to the FDA.
    Under the consent decree to reopen the plant, Abbott has agreed to bring in outside experts to help the facility come into compliance with food safety regulations, according to the Justice Department. The outside experts will design a plan for Abbott to reduce the risk of bacterial contamination at the plant and conduct periodic evaluations to make sure the company is in compliance. The process will be under FDA supervision, according to the Justice Department.
    Abbott is required to shut down production again if any products test positive for Cronobacter or Salmonella, dispose of the product, find the contamination source and correct the problem. The company cannot restart production again until it receives clearance from the FDA. If Abbott fails to comply, it would face $30,000 in damages for every day it’s in violation with the annual penalties not exceeding $5 million. The company is subject to the conditions of the consent decree for at least five years.
    Attorney General Merrick Garland, in a statement Monday, said the Justice Department would vigorously enforce U.S. food safety laws.
    In February, Abbott issued a voluntary recall of its Similac PM 60/40, Similac, Alimentum and EleCare products made at the Michigan plant. Abbott said last week that no formula distributed from the plant to consumers tested positive for the bacteria, and genetic sequencing of two samples from the sick infants did not match the Cronobacter strains found in the plant.
    The FDA concluded its inspection in March. The Centers for Disease Control and Prevention has found no additional cases of infants infected with Cronobacter after consuming products from the Michigan facility.
    The FDA, in a statement Monday, said it is working with other baby formula manufacturers to increase domestic production. Gerber increased the amount of formula available to consumers by 50% in March and April, and Reckitt has increased formula supply by more than 30% so far this year, according to the drug regulator. 
    The FDA said it will also increase baby formula imports to the U.S., which normally produces 98% of the formula that consumers buy. The drug regulator will allow the importation of formula originally produced for foreign markets, but manufacturers will have to submit applications to the FDA, which will evaluate whether the product is safe and provides enough nutrition.
    The FDA added it will prioritize applications from companies that demonstrate safety and nutritional standards and can expedite large quantities of their products to U.S. shelves. Senior Biden administration officials, in a call with reporters, said imported formula will come from countries with similar regulatory standards, such as Ireland, the U.K., Australia and New Zealand.
    The drug regulator said it also has been increasing the supply of baby formula arriving at the nation’s ports since February, with imports up more than 300% compared to last year. The FDA has been working with the U.S. Department of Agriculture and authorities in the U.K. and Europe on these imports.

    CNBC Health & Science

    Read CNBC’s latest global coverage of the Covid pandemic:

    WATCH LIVEWATCH IN THE APP More

  • in

    Jim Cramer says to consider these five high-yielding stocks to upgrade your portfolio

    Monday – Friday, 6:00 – 7:00 PM ET

    CNBC’s Jim Cramer on Monday gave investors a list of five “accidentally high yielders” that he believes will provide investors refuge in the currently unpredictable market.
    “Stick with the right groups and avoid the wrong ones — wrong ones being unprofitable tech companies or any other richly valued momentum stocks that have long since lost their momentum,” the “Mad Money” host said.

    CNBC’s Jim Cramer on Monday gave investors a list of five “accidentally high yielders” that he believes will provide investors refuge in the currently unpredictable market.
    “At the depths of the [2008] financial crisis, you got an amazing opportunity to buy the accidentally high yielders …  real companies with stable dividends that had seen their stocks come down so far that their dividends were sporting ridiculously high yields versus the old days. This moment’s becoming similar,” the “Mad Money” host said.

    “It’s worth sticking with the stock market as long as you stick with the right groups and avoid the wrong ones — wrong ones being unprofitable tech companies or any other richly valued momentum stocks that have long since lost their momentum,” he added.
    The Dow Jones Industrial Average rose 0.08% on Monday while the S&P 500 dropped 0.39%. The tech-heavy Nasdaq Composite fell 1.2%.
    Cramer previously came up with a list of stocks with high yields in March, highlighting ten names he believed were investable.
    “Of these, [Simon Property Group is] the only one I still feel confident about. … We came in too early, and we were too confident about retail. I’m not making that mistake again,” he said. “At the same time, even a high dividend isn’t enough to support a stock in a bad sector.”
    “That’s why we need to high-grade our accidental high-yielder portfolio,” he added.

    To come up with his list of accidental-high yielders, Cramer started out by looking for names in the S&P 500 to stick with the “largest of the large caps.” He pinpointed stocks that fit the following criteria:

    Does not have a yield below 3.5%
    Are down 25% or more from their highs

    Left with 21 names that fit his conditions — which included Simon Property Group and Morgan Stanley, two names that were on his last list of high-yielders — Cramer further narrowed the list to five stocks.
    Here is the list he came up with:

    Huntington Bancshares
    Truist 
    Best Buy
    Whirlpool
    Digital Realty

    Disclosure: Cramer’s Charitable Trust owns shares of Morgan Stanley.
    Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.
    Disclaimer

    Questions for Cramer?Call Cramer: 1-800-743-CNBC
    Want to take a deep dive into Cramer’s world? Hit him up!Mad Money Twitter – Jim Cramer Twitter – Facebook – Instagram
    Questions, comments, suggestions for the “Mad Money” website? [email protected]

    WATCH LIVEWATCH IN THE APP More

  • in

    How Carvana went from a Wall Street top pick to trading with meme stocks

    Carvana has gone from Wall Street’s preferred used car retailer to trading like a meme stock amid cost-cutting measures and layoffs.
    Shares of the company are down nearly 90% since November, sinking to less than $40 a share from more than $300.
    The rapid fall from grace for the Arizona-based used car retailer is a mix of changing market condition as well as self-inflicted wounds.

    Ernie Garcia, CEO, Carvana
    Scott Mlyn | CNBC

    Carvana CEO Ernie Garcia III regularly tells Wall Street that “the march continues” in the company’s mission to become the largest and most profitable used car retailer in the world.
    Its stock price has marched this year as well, just in the wrong direction for investors. Within six months, Carvana has gone from Wall Street’s preferred used car retailer poised to capitalize on a robust market to trading like a volatile meme stock amid cost-cutting measures and layoffs.

    The fall from grace for the Arizona-based used car retailer, including a nearly 90% decline in its stock price since November, resulted from a mix of changing market conditions as well as self-inflicted wounds. Many traditional dealers continue to report record or near-record results, shining further light on Carvana’s problems.
    Carvana grew exponentially during the coronavirus pandemic, as shoppers shifted to online purchasing rather than visiting a dealership, with the promise of hassle-free selling and purchasing of used vehicles at a customer’s home. But analysts are concerned about the company’s liquidity, increasing debt and growth, which this year is expected to be its slowest since becoming a public company in 2017.

    Loading chart…

    “By the company’s own admission, it had accelerated growth at precisely the wrong time into a consumer slowdown leaving a major mismatch between capacity and demand, creating a liquidity crunch,” Morgan Stanley’s Adam Jonas said in an investor note earlier this month, downgrading the company and slashing its price target to $105 a share from $360.
    The slowdown is due to high vehicle prices, rising interest rates and recessionary fears, among other factors. Carvana purchased a record number of vehicles last year amid sky-high prices and rising inflation, in preparation for unprecedented demand that has since slowed.
    Analysts say Carvana is far from out, but it may have peaked. There are concerns regarding the used vehicle market going forward as well as its near-term risks outweighing the potential rewards.

    “Deteriorating capital market conditions and worsening trends in the used vehicle industry have eroded our conviction in the path for Carvana to secure the necessary capital to realize sufficient scale and self-funding status,” Stifel’s Scott W. Devitt said last week in an investor note.
    Carvana stock is rated “hold” with a price target of $89.30 a share, according to analyst estimates compiled by FactSet.

    ‘We weren’t prepared’

    Carvana’s stock was at more than $300 a share ahead of the company reporting its third-quarter results on Nov. 4, when it missed Wall Street’s earnings expectations and internal operational problems were disclosed.
    Garcia, who also serves as chair, told investors that the company couldn’t meet customer demand, causing it to not offer its entire fleet of vehicles on its website for consumers to purchase. He said it was a result of the company purchasing vehicles at a higher rate than it could process.
    “We weren’t prepared for it,” said Garcia, who co-founded the company in 2012 and has grown it into a nearly $13 billion business.

    To assist future throughput of purchasing vehicles and times to recondition them, Carvana on Feb. 24 announced a definitive agreement to purchase the U.S. operations of Adesa – the second-largest provider of wholesale vehicle auctions in the country – from KAR Global for $2.2 billion.
    Garcia, at the time, said the deal “solidifies” Carvana’s plan to become “the largest and most profitable automotive retailer.” Ending his prepared remarks with investors for its fourth-quarter earnings that same day with, “the march continues.”
    The deal was hailed by investors, who sent the stock up 34% over the next two days to more than $152 a share. It followed a steady decline due to recessionary fears and other macroeconomic trends impacting the used car market.

    Overbuilt costly inventory

    The gains from the deal were short-lived due to the macroeconomic environment and the company significantly missing Wall Street’s expectations for the first quarter, initiating a sell-off of the company’s stock and a host of downgrades by analysts.
    The company was criticized for spending too much on marketing, which included a lackluster 30-second Super Bowl ad, and not preparing for a potential slowdown or downturn in sales. Carvana argues it overprepared for the first quarter, after being underprepared for the demand last year.
    “We built for more than showed up,” Garcia said during an earnings call April 20.

    Source: NYSE

    The results tanked shares during the following week. Garcia described the problems as “transitory” and something the company will learn from. He admitted that Carvana may have been prioritizing growth over profits, as the company pushed back plans to achieve positive earnings before interest and taxes by “a few quarters.”
    The stock was hit again in late April, when the online used-car dealer struggled to sell bonds and was forced to turn to Apollo Global Management for $1.6 billion to salvage the agreement to finance the Adesa deal.
    Analysts view the deal to finance the purchase of Adesa as “unfavorable,” at a rate of 10.25%. Its existing bonds were already yielding upwards of 9%. Bloomberg News reported Apollo saved the deal after investors were demanding a yield of around 11% on a proposed $2.275 billion junk bond and around 14% on a $1 billion preferred piece.

    Stock picks and investing trends from CNBC Pro:

    The unfavorable terms will “inevitably delay the path” to positive free cash flow for the company until 2024, said Wells Fargo analyst Zachary Fadem. In a note to investors on May 3, he downgraded the stock and cut its price target from $150 to $65 a share.
    RBC Capital Markets’ Joseph Spak voiced similar concerns about the deal, saying the integration “could be messy” during the next two-plus years. He also downgraded the stock and cut its price target.
    “While the strategic rationale for Adesa makes sense, in our view, retrofitting and staffing up 56 facilities over the next couple years is likely to face a prolonged period of operating inefficiencies with as much as 18-24 months of ongoing bottom-line risk upcoming,” he said in an investor note early last month.

    Meme status

    Carvana shares last week hit a two-year low before surging as much as 51% the same day along with “meme stocks” such as GameStop and AMC.
    Meme stocks refer to a select few stocks that gain sudden popularity on the internet and lead to sky-high prices and unusually high trading volume.
    For example, trading volume for Carvana on Thursday was over 41.7 million, compared with its 30-day average volume of about 9 million. Trading of Carvana shares on Thursday was halted at least four times.  
    Nearly 29% of Carvana shares available for trading are sold short, according to FactSet, among the highest ratios on U.S. markets.

    Carvana is attempting to get back into Wall Street’s good graces. In an investor presentation released late-Friday, the company defended the Adesa deal and updated its growth and cost-cutting plans, including lowering its vehicle acquisition costs.
    The company said it’s refocusing its three key priorities: growing retail units and revenue, increasing total gross profit per unit and demonstrating operating leverage.
    “We have made significant progress on the first two objectives,” the company said. However, it said it needed to do more, specifically regarding profitability, free cash flow, and selling, general and administrative costs.
    The company, in the presentation, reconfirmed reports last week that it cut 2,500 employees, or about 12% of its total workforce, and that the Carvana executive team would forego salaries for the remainder of the year to contribute to severance pay for terminated employees.

    Rivals’ record profits

    Carvana’s recent troubles come as the country’s largest public dealer groups continue to report record or near-record profits amid low inventories and high prices.
    The country’s largest auto retailer, AutoNation, last month reported record first-quarter earnings per share of $5.78. The company has aggressively moved into used vehicles amid a decline in new vehicle availability during the coronavirus pandemic. Revenue for its used-car business was up 47% for the quarter, pushing its overall revenue to nearly $6.8 billion.
    Lithia Motors, which is in the midst of an aggressive growth plan to become the country’s largest vehicle retailer, said its profit more than doubled during the first quarter from a year earlier to $342.2 million. Average gross profit per unit for used vehicles — a stat closely watched by investors — rose 32%, to $3,037. That compares with Carvana at $2,833.
    “Carvana seems to have gotten a lot of that tech stock halo that Tesla’s also benefited from for a long time,” said Morningstar analyst David Whiston, who covers major publicly traded dealership groups but not Carvana. “I think maybe that was a tad generous by the market.”
    – CNBC’s Michael Bloom and Hannah Miao contributed to this report.

    WATCH LIVEWATCH IN THE APP More

  • in

    Cramer's lightning round: I want to buy more Marvell Technology

    Monday – Friday, 6:00 – 7:00 PM ET

    It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.

    Loading chart…

    Marvell Technology Inc: “They are the best when it comes to 5G, the best in high-performance computing. But remember, those things have fallen out of favor right now. … I’d like to buy more [for the Charitable Trust.] That’s the way to go.”

    Loading chart…

    Stem Inc: “It got very, very high. We moved away from companies that don’t make money. … We’re not recommending stocks that don’t [make] money.”

    Loading chart…

    AbCellera Biologics Inc: “They do make money, and I will give them that, although it’s not exciting when you’ve got so many great companies like Pfizer that make a lot of money and are inexpensive.”

    Loading chart…

    Loading chart…

    Capri Holdings Ltd: “I think it’s okay, but apparel is very out of favor with this market.”
    Disclosure: Cramer’s Charitable Trust owns shares of Marvell Technology.

    WATCH LIVEWATCH IN THE APP More